NCT02491528View on ClinicalTrials.gov

A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety

PHASE3CompletedINTERVENTIONAL
Enrollment

563

Participants

Timeline

Start Date

June 19, 2015

Primary Completion Date

August 12, 2016

Study Completion Date

August 12, 2016

Conditions
Diabetes
Interventions
BIOLOGICAL

insulin Aspart injection

Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.

BIOLOGICAL

insulin Aspart injection (NovoRapid)

Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.

Trial Locations (2)

Unknown

Affiliated hospital of Weifang Medical University, Weifang

The 6th people's hospital of Shanghai, Shanghai

All Listed Sponsors
lead

Tonghua Dongbao Pharmaceutical Co.,Ltd

INDUSTRY

NCT02491528 - A Phase III Study of Insulin Aspart Injection to Evaluate the Efficacy and Safety | Biotech Hunter | Biotech Hunter